PIPELINE
Robust pipeline with wholly-owned and partnered programs
Program
Target Class
Discovery
Lead ID
Preclinical
IND-E
Oncology
Checkpoint
Partnered
Cardiovascular
PAR1*
PAR1*
GPCR
Wholly-owned
Oncology
TMR
Partnered
CNS
GPCR
Partnered
Undisclosed
GPCR
Partnered
Idiopathic Pulmonary Fibrosis
GPCR
Wholly-owned
MASH
Cardiometabolic diseases
Cardiometabolic diseases
PAQR
Wholly-owned
* PAR1 program also has attractive development potential for Triple Negative Breast Cancer (Singh DD et al, 2021). Antiverse has not prosecuted this to date.